Patrick Daly

DocwireNews

According to Lucia Masarova and colleagues, the median therapy duration of ruxolitinib&mdash;a JAK inhibitor used in patients with advanced-phase myelofibrosis (MF)&mdash;is about three years. The researchers examined patients who had been treated with ruxolitinib for three years or more, and reported that 40% of patients who received ruxolitinib for &ge;3 years survived to 10 years post-initiation.In their report, featured at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the researchers specified that &ldquo;age remains the major predictive factor of survival despite long ruxolitinib therapy.&rdquo;The retrospective study included a total of 131 patients who had received ruxolitinib for three or more years. The primary measures of the analysis were the associations between clinical characteristics and therapy details and the overall survival (OS) rate at treatment initiation and in the years following.According to the abstract, among 62 patients with &ge;28 gene sequencing data available, 19, 24, and 19 patients had zero, one, and &ge;2 mutations, respectively, beyond JAK2, MPL, CALR. The median time to treatment initiation from presentation and MF diagnosis was four and 11 months, respectively. The median duration of ruxolitinib therapy was 76 months (95% confidence interval, 56&ndash;88).Notably, the factors associated with OS in univariate analysis were age over 65 years, neutrophils percentage, blasts percentage, and Eastern Cooperative Oncology Group (ECOG) performance status below two. However, only age over 65 years and neutrophil percentage remained significant in multivariate analysis.Overall, the authors presented their data as supportive of ruxolitinib therapy in patients with advanced phases of MF over the long-term.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Examining Patients With Myelofibrosis on Ruxolitinib for Three or More Years

ASCO 2022

According to Lucia Masarova and colleagues, the median therapy duration of ruxolitinib—a JAK inhibitor used in patients with advanced-phase myelofibrosis (MF)—is about ...

Examining Patients with Myelofibrosis on Ruxolitinib for Three or More Years

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe